Cencora Beats Revenue and EPS Estimates as Quarterly Sales Reach $88.4 Billion
Cencora guided fiscal 2027 adjusted diluted EPS to $19.40 to $19.75, a range that sits just below the $19.76 average analyst estimate.
Cencora COR
Cencora, Inc. · NYSE · Wholesale-Drugs, Proprietaries & Druggists' Sundries
$340.50+0.79%close on Nov. 3, 2026 · volume 1.6M · Yahoo Finance
Price, last 51 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Nov. 2, 2026 | Lazarus Krikorian SVP & Chief Accounting Officer | Sold 10b5-1 plan | 986 | $330.96 | $326,327 |
| Oct. 1, 2026 | Lazarus Krikorian SVP & Chief Accounting Officer | Sold 10b5-1 plan | 986 | $303.18 | $298,935 |
| Sept. 16, 2026 | Lon R. Greenberg director | Sold | 1,280 | $321.30 | $411,264 |
| Sept. 1, 2026 | Lazarus Krikorian SVP & Chief Accounting Officer | Sold 10b5-1 plan | 985 | $325.97 | $321,080 |
| Aug. 24, 2026 | Elizabeth S. Campbell Executive Vice President | Sold | 11,300 | $324.12 | $3.66 million |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 21 →Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedCencora Q4 Adjusted EPS $4.66 Beats $4.57 Consensus, but FY2027 Adjusted EPS Guidance of $19.40-$19.75 Sits Below $19.76 Consensus
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedCencora to acquire American Oncology Network for $2.3 billion at closing plus up to $100 million CVRs; raises low end of FY2026 adjusted EPS to at least $17.90